Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety profile among patients, according to a study. “Dermatomyositis is a ...
Dermatomyositis (DM) is a chronic autoimmune disease characterized by inflammatory myopathy and distinctive skin ...
Dazukibart, an anti–interferon beta monoclonal antibody, showed potential in reducing dermatomyositis symptoms, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback